Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
MENLO PARK, Calif., Aug. 28, 2012 /PRNewswire/ -- Joseph Rogers, Ph.D., has joined SRI's Biosciences Division as executive director of a new Health Sciences Section that brings together researchers from SRI's Center for Health Sciences, led by Gary Swan, Ph.D., with SRI's Center for Neuroscience and Metabolic Diseases, led by Thomas Kilduff, Ph.D. This combination offers SRI clients and partners more integrated bench-to-bedside capabilities in areas such as addiction, alcoholism, Alzheimer's and Parkinson's diseases, Down syndrome, sleep disorders, and more.
"We are fortunate to have Joe Rogers leading the new Health Sciences Section at SRI," said Walter H. Moos, Ph.D., vice president, Biosciences Division at SRI. "Joe is an outstanding, award-winning researcher whose focus on age-related neurologic diseases will be a valuable asset to SRI's expanded health research, drug discovery, and drug development programs."
Rogers is best known for showing that inflammatory responses occur in almost all major age-related brain disorders and cause substantial damage, with his seminal paper in the area receiving nearly 1200 citations to date. Before joining SRI, Rogers served as founder and president of the Sun Health Research Institute (acquired by Banner Health System). Under his leadership the institute became internationally recognized for its research on age-related neurological diseases, and is a National Institutes of Health (NIH) funded National Alzheimer's Disease Center.
He has served on numerous boards including the American Geriatrics Society, Arizona Alzheimer's Association, NIH Working Group on Neuroimmunology, Arizona Governor's Task Force on Alzheimer's Disease, Arizona Legislative Task Force on Stem Cell Research, and the Pacific Alzheimer's Institute. A reviewer and editorial board member for numerous scientific journals, Rogers has more than 150 scientific publications. His research on Alzheimer's disease has been continuously funded by the NIH for the last 25 years. Rogers also holds patents related to the diagnosis and treatment of Alzheimer's disease.
He has received many awards for his work, including a Lifetime Achievement Award from Arizona Business Magazine, a Lifetime Achievement Award from Phoenix Business Journal, and a Lifetime Achievement Award, a Zenith Award, and a Faculty Scholar Award from the national Alzheimer's Association. Rogers received his Ph.D. from the University of California, San Diego, his B.A. from Emory University, and was a Postdoctoral Fellow at the Salk Institute.
About SRI's Biosciences Division
SRI's Biosciences division carries out basic research, drug discovery, and drug development, and provides contract (CRO) services. SRI has all of the resources necessary to take R&D from "Idea to IND"®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and commercial clients and partners advance many drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.
About SRI International
Innovations from SRI International have created new industries, billions of dollars of marketplace value, and lasting benefits to society—touching our lives every day. SRI, a nonprofit research and development institute based in Silicon Valley, brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Government and business clients come to SRI for pioneering R&D and solutions in computing and communications, chemistry and materials, education, energy, health and pharmaceuticals, national defense, robotics, sensing, and more.
SOURCE SRI International